Antibody System Anti-Insulin Glargine hIgG ELISA Kit
This enzyme-linked immunosorbent assay (ELISA) kit is engineered for the precise quantitative determination of human IgG-class anti-drug antibodies (hIgG ADAs) directed against Insulin Glargine in serum and plasma samples. Insulin Glargine is a long-acting recombinant human insulin analog containing a glycine substitution at position A21 and two arginine additions at the C-terminus of the B-chain. These structural modifications shift its isoelectric point, enabling the formation of a subcutaneous depot that slowly dissolves to provide a flat, peakless basal insulin profile over 24 hours. Despite its major therapeutic benefits for patients with Type 1 and Type 2 diabetes mellitus, chronic exposure can induce an immune response, driving the generation of specific anti-drug antibodies. The human IgG class represents the predominant isotype involved in secondary humoral immune responses and can directly impact drug pharmacokinetics, alter clearance rates, or act as precursors to neutralizing antibody profiles. This indirect ELISA platform serves as a vital analytical instrument for clinical investigators, immunologists, and biosimilar manufacturers assessing drug immunogenicity profiles, monitoring patient safety, and verifying bioequivalence across development tracks.
PRODUCT INFO
Principle of the Assay
This assay utilizes a high-performance, solid-phase quantitative indirect enzyme immunoassay technique to measure target human IgG anti-drug antibody levels:
-
Target Capture: Recombinant Insulin Glargine is uniformly pre-coated onto the solid-phase surface of a 96-well microplate.
-
Specific Binding: Calibrated standards or unknown biological samples are pipetted into the microwells. Endogenous Anti-Insulin Glargine hIgG antibodies present in the sample are bound and securely immobilized by the pre-coated protein matrix.
-
Secondary Detection: Unbound matrix elements are removed via a thorough wash cycle. A biotin-labeled Mouse Anti-Human IgG monoclonal secondary antibody is introduced into the wells, binding selectively to the captured human IgG target fractions.
-
Enzyme Complexing: Following another wash step to clear away unbound secondary antibodies, Streptavidin conjugated to Horseradish Peroxidase (Streptavidin-HRP) is added, anchoring specifically to the biotinylated domains.
-
Signal Amplification and Readout: After a final wash to remove excess enzyme reagent, a colorimetric substrate solution is added to initiate enzymatic signal development. Because this is an indirect sandwich configuration, the resulting color intensity develops in direct proportion to the concentration of Anti-Insulin Glargine hIgG bound in the initial step. The reaction is terminated with a stop solution, and absorbance is quantified spectrophotometrically.
Key Features and Performance Metrics
-
Ultra-Sensitive Detection Capability: Exhibits an exceptional analytical sensitivity down to 2.82 ng/mL, facilitating the early tracking of trace human IgG anti-drug antibody formations.
-
High-Resolution Quantitative Range: Delivers a refined linear tracking range from 3.13 ng/mL to 200 ng/mL, optimized for the highly accurate profiling of precise, low-level antibody titers.
-
Exceptional Intra-Assay Precision: Demonstrates outstanding target reproducibility with a Coefficient of Variation (CV) of less than 10 percent, validated through sixteen separate replicate evaluations across three samples of known concentration on a single test plate.
-
Outstanding Inter-Assay Uniformity: Confirms high day-to-day and batch-to-batch experimental reliability with a CV of less than 15 percent, verified across twenty-four distinct assay runs using three independent reference concentration samples.
Technical Specifications
-
Catalog No.: KAB94002
-
Assay Configuration: Quantitative Indirect Enzyme Immunoassay
-
Targeted Biomarker: Anti-Insulin Glargine Human IgG (hIgG ADA)
-
Validated Matrices: Serum and Plasma
-
Assay Range: 3.13 to 200 ng/mL
-
Analytical Sensitivity: 2.82 ng/mL
-
Solid-Phase Target: Recombinant Insulin Glargine
-
Detection Layer: Biotinylated Mouse Anti-Human IgG / Streptavidin-HRP
Applications and Workflow Summary
This indirect ELISA platform is highly optimized for therapeutic drug immunogenicity monitoring, biosimilar validation, and longitudinal humoral response profiling. Investigators should observe the following guidelines:
-
Dilution and Layout: Unknown serum or plasma matrices must be screened alongside the provided reference standards. Samples exhibiting target concentrations exceeding the maximum range of 200 ng/mL must be diluted empirically in standard assay matrix buffer prior to running the assay.
-
Analysis Requirements: To achieve absolute quantification accuracy, investigators must generate a standard curve simultaneously during every plate run, plotting standard absorbance profiles against log-transformed concentration values.
Handling, Stability and Storage
-
Kit Shipping: Distributed under secure, temperature-controlled conditions on blue ice or chilled gel packs to preserve protein matrix and enzyme binding configurations.
-
Operational Stability: Built with high-grade components to guarantee consistent, low-decay signal retention over a standard six-month framework when kept at the manufacturer-specified storage parameters.
-
Storage Guidance: Keep the complete kit stored strictly at the recommended refrigeration temperature upon receipt. Ensure that unused microplate wells remain sealed within their original desiccant pouch to guard against moisture compromise.
-

















